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ntravascular Ultrasound in the Drug-Eluting Stent Era
ary S. Mintz, MD,* Neil J. Weissman, MD†
ew York, New York; and Washington, DC
Intravascular ultrasound (IVUS) has become an indispensable part of all drug-eluting stent
(DES) studies; findings must be put into context with the IVUS findings in bare metal stents.
Unfortunately, there is not yet a complete picture of either the Cypher (Cordis, Miami,
Florida) or the Taxus (Boston Scientific, Maple Grove, Minnesota) stent (the two U.S. Food
and Drug Administration-approved devices). Intimal hyperplasia volume in DES is reduced
to 15% of stent volume, but stent underexpansion continues to be a consistent finding in
DES failures (restenosis and thrombosis). The utility of IVUS to assure adequate stent
expansion may be more important whenever there are clinical risk factors for DES
failure. (J Am Coll Cardiol 2006;48:421–9) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.04.068Cardiology Foundation
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cn the bare-metal stent (BMS) era serial (post-intervention
nd follow-up) intravascular ultrasound (IVUS) was cru-
ial to understanding how stents worked and why they
ailed. Chronic stent recoil was rare, and late lumen loss
as almost entirely the result of intimal hyperplasia (IH)
1). To date, IVUS studies of most DES devices have
ainly reported and compared percentage IH (%IH)
olume, an IVUS measure of efficacy (Fig. 1). Only the
VUS results from the sirolimus-eluting Cypher stent (Cor-
is, Miami, Florida), the polymeric paclitaxel-eluting Taxus
tent (Boston Scientific, Maple Grove, Minnesota), and a
onpolymeric paclitaxel-eluting stent have been studied and
eported in detail. This review focuses on the two U.S. Food
nd Drug Administration (FDA)-approved devices, Cypher
nd Taxus.
NTIMAL HYPERPLASIA
n BMS, %IH volume averaged 30% of stent volume; %IH
olume was consistently greater in diabetics versus nondia-
etics; and in BMS that did not restenose, IH remained
table or regressed slightly after 6 months.
ypher stent. In the RAVEL (Randomized Comparison
f a Sirolimus-Eluting Stent with a Standard Stent for
oronary Revascularization) trial, 6-month %IH volume
1  3%) was lower with Cypher stents compared with
ontrol subjects (29  20%; p  0.001) (2). In the subset
f diabetic patients, Cypher stent %IH volume measured
.82  1.38% (vs. 30.2  22.9% in control subjects; p 
.008). Furthermore, Cypher stents compared favorably in
iabetics versus nondiabetics in whom %IH volume mea-
ured 1.14  2.68% (3).
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VUS equipment. Dr. Weissman receives grant support and honoria from Boston
cientific.I
Manuscript received January 12, 2006; revised manuscript received March 15,
006, accepted April 4, 2006.In the SIRIUS (Sirolimus-Eluting Stent in Coronary
esions) trial, Cypher stents reduced 9-month %IH vol-
mes from 33.4% to 3.1% (p  0.001) (4). There was a
endency for greater neointima suppression in the middle of
he stent compared with the edges, the opposite of BMS
5). There was: 1) no difference in IH between lesions with
oderate/severe calcium (arc 120°) versus no/mild cal-
ium; 2) no difference between lesions with positive versus
egative pre-intervention vessel remodeling; 3) no correla-
ion between IH and pre-interventional plaque burden
plaque and media [P&M]/external elastic membrane
EEM]); 4) no effect from stent asymmetry; and 5) no
ifference between overlap versus nonoverlapped segments
6–8). Many weak predictors of BMS restenosis (i.e.,
re-intervention positive remodeling and pre-intervention
r residual plaque burden) were not predictive after Cypher
mplantation, because marked IH suppression masked any
ffect from weaker predictors.
In the São Paulo registry, IH within Cypher stents was
table or increased slightly beyond the time points reported
n the RAVEL (6 months) and SIRIUS (9 months) trials.
he %IH volume in 14 patients treated with the fast-release
ormulation was 2.3% at 1 year, 9.2% at 2 years, and 9.1% at
years; %IH volume in 14 patients treated with the
low-release formulation was 2.2% at 1 year, 3.3% at 2 years,
nd 5.7% at 4 years (9–11).
axus stent. In the TAXUS-II trial, 6-month %IH vol-
me measured 7.8  9.9% in slow-release Taxus stents (vs.
3.2  18.2% in control subjects) and 7.8  9.7% in
oderate-release Taxus stents (vs. 20.5  16.7% in control
ubjects) (12). The distribution of IH over the length of the
tent was neither increased (as in BMS) nor more sup-
ressed in the center (as in Cypher) (13).
The findings of the TAXUS-II trial were supported by
he TAXUS-IV trial (14); 9-month %IH measured 12.2 
2.4% in slow-release Taxus stents versus 29.4  14.0% in
ontrol subjects (p  0.0001). As in the TAXUS-II trial,
H was flat over the length of the stent.
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IVUS and DES August 1, 2006:421–9The TAXUS-V trial randomized more complex lesions
han the TAXUS-IV trial; %IH volume measured 13.2 
2.0% with Taxus stents versus 31.8  15.1% with control
ubjects (p  0.0001) (15). The TAXUS-VI trial studied
oderate-release Taxus stents in longer lesions; %IH vol-
me measured 10.7 10.8% versus 33.0 15.1% in control
ubjects (p  0.0001) (N. J. Weissman, unpublished data,
005).
A subset meta-analysis of 566 patients from the TAXUS-
V, V, and VI trials showed: 1) %IH measured 9.8 12.0%
n overlapping Taxus segments versus 11.3  10.9% in
onoverlapping segments; and 2) in lesions 26 mm in
ength, %IH measured 13.4  9.2% (N. J. Weissman,
npublished data, 2005) In that meta-analysis, %IH in 87
iabetics treated with Taxus stents measured 13.7  12.4%,
.e., less than the 34.6  16.7% in 75 diabetics treated with
MS (p  0.0001) but no different from the 217 nondia-
etics treated with Taxus stents (11.6  11.6%) (16).
Two-year TAXUS-II IVUS trial data has been reported
n a highly selected group of 32% of Taxus-treated patients
ho had baseline and 6 month follow-up IVUS. The IH
ontinued to be significantly suppressed compared with
MS. However, IH increased in both the slow-release and
oderate-release Taxus stents (0.64  0.81 mm2 to 0.94 
Abbreviations and Acronyms
BMS  bare-metal stent
CSA  cross-sectional area
EEM  external elastic membrane
IH  intimal hyperplasia
ISR  in-stent restenosis
IVUS  intravascular ultrasound
LAD  left anterior descending
LMCA  left main coronary artery
LSM  late stent malapposition
MSA  minimum stent CSA
P&M  plaque and media
igure 1. This illustration shows the percentage intimal hyperplasia volum
r nonpolymeric) and the name of the trial are shown. The time point of th
epending on the trial. (By comparison, after implantation of bare metal stents
C  phosphorylcholine..76 mm2 [p  0.01] and 0.66  0.83 mm2 to 1.06  0.90
m2 [p  0.009], respectively) (17).
DGE EFFECTS
are-metal stent implantation caused progressively more
EM cross-sectional area (CSA) decrease (negative remod-
ling) and progressively less P&M CSA or IH increase at
reater distances from the stent edges (1).
ypher stent. In the RAVEL trial, IVUS was only per-
ormed at follow-up; therefore, edge effects, requiring serial
VUS imaging, were not addressed. Of 31 Cypher failures
n the SIRIUS trial, 27 restenoses were focal and 19 were at
he stent edges. Larger reference plaque burdens and larger
dge stent CSA/reference minimum lumen CSAs were
ssociated with Cypher edge restenosis, suggesting that
ncomplete lesion coverage—landing the stent edge
ithin a plaque (even a secondary plaque)— contributed
o edge restenosis (18). Cypher edge restenosis was asso-
iated with negative remodeling (EEM decrease) in the first
to 3 mm as well as a focal increase in IH just at the edge
f the stent (19).
axus stent. In the TAXUS-II trial, when analyzed mm
y mm, there was an increase in EEM CSA, an increase in
&M CSA, and a decrease in lumen CSA within the first
mm proximally and within the first 3 mm distally in both
low- and moderate-release Taxus stents. (Edge effects were
ess obvious when proximal and distal 5-mm–long segments
ere analyzed as a volume.) EEM or P&M were similar
omparing proximal and distal edges; however, there was a
arger decrease in lumen CSA at the proximal versus the
istal edges in both moderate- and slow-release groups (20).
n both the TAXUS-IV (14) and TAXUS-VI (N. J.
eissman, unpublished data, 2005) trials, there was also a
ignificant increase in distal lumen CSA at follow-up but no
ignificant change in proximal lumen CSA.
trials of drug-eluting stents. The drug and its carrier vehicle (polymeric
avascular ultrasound analysis ranged from 4 to 9 months after implantatione from
e intrpercentage intimal hyperplasia volume averages 30%.) NO  nitric oxide;
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August 1, 2006:421–9 IVUS and DESASCULAR RESPONSES
n BMS, vascular responses to stent implantation were not
imited to the luminal side of the stent or to the proximal
nd distal reference segments. Abluminal (peri-stent) EEM
nd P&M both increased (1).
Vascular responses with DES were not well studied. In an
nalysis of 30 patients in the São Paulo registry, peri-stent
&M volume did not change in the first 2 years after
ypher stent implantation but decreased between 2 and 4
ears as the plaque became more echoreflective (21). In an
nalysis of the TAXUS-II trial patients, there was a greater
-month increase in peri-stent EEM CSA in the moderate-
elease group compared with control subjects (but not in the
low-release group compared with control subjects), sug-
esting a dose-dependent drug effect (13). At 2 years, the
-month peri-stent increases in EEM and P&M regressed
ompletely in the slow-release group but only incompletely
n the moderate-release group (17).
igure 2. This patient underwent Cypher stent implantation in a right co
focal angiographic aneurysm in the proximal right coronary (arrow). The fi
n D. Note the late stent malapposition most prominently indicated by
2 2ross-sectional area (CSA) from 17.8 mm to 28.9 mm along with an increase in
rom 8.8 mm2 to 16.8 mm2. The stent CSA (8.8 mm2) and the peri-stent plaqATE STENT MALAPPOSITION (LSM)
ate stent malapposition (also called late acquired incom-
lete stent apposition) occurred in approximately 4% to 5%
f BMS, was caused by an increase in EEM that was greater
han the increase in peri-stent P&M, but was not associated
ith adverse events (1).
ypher stent. Because the RAVEL trial did not include
ost-intervention IVUS, the high rate of Cypher stent
alapposition at follow-up (21% vs. 4% in control subjects)
ould not be separated into acquired versus persistent
alapposition (2). In the SIRIUS trial, which had IVUS
oth at implantation and follow-up, LSM was seen in 8.7%
f Cypher stents versus none in control subjects (p  0.05)
Fig. 2) and was associated with an increase in peri-stent
EM CSA. There were no deleterious clinical events in any
f these 19 patients at 12 months after stent implantation
22). A longer-term follow-up IVUS study from the RAVEL
rial indicated that malapposition discovered at 6 months
stenosis; the final angiogram is shown in A. At follow-up (B) there was
post-implantation) IVUS is shown in C, and the follow-up IVUS is shown
hite asterisk. There has been an increase in external elastic membraneronary
nal (
the w
effective lumen CSA (intra-stent lumen CSA plus area of malapposition)
ue and media CSA (8.9 mm2) have not changed.
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IVUS and DES August 1, 2006:421–9fter implantation neither progressed nor regressed over the
ubsequent 12 months (23).
axus stent. In the TAXUS-II trial, LSM at 6 months was
een in 8.0% of slow-release and 9.5% of moderate-release
axus stents (p  0.3 vs. 5.4% in controls). The LSM was
aused by an increase in EEM with no increase in peri-stent
&M, and LSM detected at 6 months was not associated
ith adverse events at 12 months (including no stent
hromboses) (24). In a subset of patients studied at 2 years,
he incidence of LSM was 0% in the slow-release group
down from 9.3%) and 2.4% in the moderate-release group
down from 9.8%) (17).
In the TAXUS-IV trial, LSM was seen in 1.1% of
low-release Taxus stents versus 2.2% of control subjects
14). In the TAXUS-V trial, LSM was seen in 8.7% of
low-release Taxus stents versus 4.1% of control subjects
p  0.3) (15). And in the TAXUS-VI trial, LSM was seen
n 16.7% of moderate-release Taxus stents versus 4.3% of
ontrol subjects (p  0.018). Finally, in a meta-analysis of
he TAXUS-IV, -V, and -VI trials, 9-month LSM was
ore common in Taxus than in control stents (8.4% vs.
.5%; p  0.02); this was predominantly driven by non–
DA-approved moderate-release Taxus stent use in the
AXUS-VI trial. The LSM was associated with less IH
han fully apposed stents. One year later, there were no
ajor adverse cardiac events (including stent thromboses) in
ny patient with LSM (25).
san Medical Center experience. Hong et al. (26) eval-
ated LSM in 557 patients. Late stent malapposition
ccurred in 13.2% of 538 Cypher versus 8.4% of 167 Taxus
tents (p  0.12). The frequency of LSM increased after
irectional coronary atherectomy before stenting (25%),
fter primary stenting in acute myocardial infarction (MI)
32%, suggesting that thrombus dissolution may be impor-
ant in infarct lesions that develop LSM), and in chronic
otal occlusions (27.5%). Independent predictors of LSM
ere total stent length, primary stenting in acute MI, and
cclusions. In the subgroup of elective stenting after con-
entional balloon predilation, the only independent predic-
or of LSM was total stent length. There were no adverse
vents from implantation to when LSM was detected at 6
onths or during the subsequent 12 months.
Thus, current experiences do not suggest any definite
linical sequelae from LSM. However, exaggeration of the
echanisms responsible for LSM can cause aneurysm
ormation.
ES THROMBOSIS
n BMS, minimum stent area (MSA) and stent expansion
MSA divided by the mean reference lumen CSA) were
maller, calcification was rare, and dissections were common
hen stent thromboses were compared to nonthrombosed
tents (1).
ypher stent. Fifteen patients who developed Cyphertent thrombosis were compared with 45 matched control subjects. The MSA measured 4.3  1.6 mm2 in Cypher
hrombosis (vs. 6.2  1.9 mm2 in control subjects; p 
.001); stent expansion was smaller (65  18% vs. 85 
4%; p  0.001); and a residual edge stenosis (reference
inimum lumen CSA 4 mm2 with a plaque burden
70%) was more common in the thrombosis group (67%
s. 9%; p  0.001). However, there was no difference in the
ate of acute or late stent malapposition between the two
roups (27).
axus stent. There have been no IVUS studies of Taxus
tent thrombosis.
ate thrombosis. In a study of 11 patients (8 with Cypher
tents) with late (12 months) stent thrombosis, stent
xpansion (58  25%) was less than in patients without late
tent thrombosis (81  17%; p  0.001); and incomplete
tent apposition was more common (55% vs. 12%; p 
.0001) (28).
ES RESTENOSIS
hen a patient presented with BMS restenosis, IVUS often
howed either stent underexpansion or another mechanical
omplication. The single major IVUS predictor of clinical,
ngiographic, or IVUS BMS restenosis was the absolute
nal MSA (1).
ypher stent failure. In a substudy of the SIRIUS trial
here adequate patency was defined as a follow-up IVUS
inimum lumen CSA 4 mm2, the post-intervention
SA that best separated “adequate” from “inadequate”
atency was 5.0 mm2. The positive predictive value for this
ut-off point was 90%, suggesting that Cypher failure in the
IRIUS trials was mostly due to stent underexpansion at the
ime of implantation (29).
In a study of 550 patients with 670 native coronary artery
esions treated with Cypher stents, IVUS cut-offs that best
redicted angiographic restenosis were an MSA of 5.5 mm2
nd a stent length of 40 mm. When patients were divided
nto subgroups, angiographic restenosis rates were 0.4%
MSA 5.5 mm2 and stent length 40 mm), 2.4% (MSA
5.5 mm2 and stent length 40 mm), 8.6% (MSA 5.5
m2 and stent length 40 mm), and 17.7% (MSA 5.5
m2 and stent length 40 mm) (30).
In one IVUS study of 33 Cypher failures, an MSA 5.0
m2 was observed in 67% (31). In another study of 26 DES
ailures (21 Cypher stents), MSA measured 4.6 1.5 mm2;
1% had an MSA 5.0 mm2, and 38% had an MSA 4.0
m2 (32).
Stent underexpansion is the most common mechanism of
ypher failure. Once IH is suppressed, the impact of stent
nderexpansion becomes magnified. However, in an analy-
is of 48 Cypher restenoses, 71% of stents had an MSA
5.0 mm2 somewhere within the stent, but this occurred at
he minimum lumen site in only 46.9%. Therefore, other
echanisms must be considered (33).
Cypher stent failure has also been attributed to eithertrut fractures or gaps between adjacent stent struts (34).
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August 1, 2006:421–9 IVUS and DESecause transducer angulation can affect the number and
istribution of the struts seen on a single frame, the
iagnosis of strut fracture requires IVUS documentation of
tent struts present immediately after the procedure that are
o longer seen at follow-up, not merely a paucity of struts at
ollow-up (Fig. 3). It is not clear whether strut fractures
ccur with BMS or whether they have been missed, and it
s not clear whether Cypher strut fracture is a common or
ncommon cause of restenosis. Circumferential stent strut
xpansion homogeneity can be unpredictable. In 24 Cypher
estenoses the minimum lumen site had a larger maximum
nterstrut angle and fewer stent struts even when normalized
or the number of stent cells compared to nonrestenotic sites
nd stents. By implication, circumferential stent strut dis-
ribution affected the dose of sirolimus delivered to the
rterial wall and therefore the amount of IH (Fig. 4) (35).
igure 3. This long right coronary artery stenosis (A, arrow) was treated w
esult in B. At 7-month follow-up there was focal in-stent restenosis (C
follow-up IVUS) show identical image slices. At the site of focal intimal
easured 2.0 mm2, and there was a paucity of stent struts (actually, only 1
ery focal and extended for 2 mm proximally and distally. This is an exa
ere apparent at implantation that were not seen at follow-up).here were fewer stent struts in restenotic lesions with Fdequate stent expansion than in lesions with an MSA5.0
m2 at the minimum lumen site. (33).
axus stent. There are no data regarding predictors of
axus stent failure (i.e., the importance of stent underex-
ansion), stent strut fracture, or effect of nonuniform strut
istribution.
ES TREATMENT OF
ARE-METAL IN-STENT RESTENOSIS
ypher stent. The randomized INDEED (Treatment of
N-stent Restenosis with Drug-Eluting Stent versus
ntracoronary bEta-raDiation) trial reported less recur-
ent IH after Cypher stent implantation (0.84  0.78
m2) versus intracoronary brachytherapy (1.39  1.46
m2) (p  0.048) (S-J. Parks, unpublished data, 2005).
o overlapping Cypher stents (33 mm and 15 mm in length) with the final
w). D (final post-implantation intravascular ultrasound [IVUS]) and E
plasia (E, white asterisk), the minimum lumen CSA (line of white dots)
strut) compared with the same image slice in D. Intimal hyperplasia was
of focal intra-Cypher stent restenosis, probably from strut fracture (strutsith tw
, arro
hyper
stenteres et al. (36) reported less recurrent IH after Cypher
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IVUS and DES August 1, 2006:421–9mplantation (9.8  6.3 mm3) in 25 patients treated with
ypher stents versus 25 patients treated with beta-
rradiation (18  14 mm3) (p  0.0001). Conversely, in
he randomized SISR (Sirolimus-Eluting Stent Versus
rachytherapy in Patients With Bare Metal In-Stent
estenosis) trial, mean recurrent IH was similar after
ypher implantation (0.5  0.8 mm3/mm) and after
rachytherapy (0.2  1.0 mm3/mm) (p  0.3), although
roportionately fewer brachytherapy-treated patients
ere available for analysis, which might have biased the
ndings (37).
Nevertheless, the recurrence rate is higher after Cypher
reatment of BMS restenosis than after de novo implanta-
ion (38). In 1 study, 9 of 11 patients who failed Cypher
tent treatment of BMS restenosis had an MSA 5.0 mm2
ersus 5 of 19 nonrecurrences (p  0.003); 7 recurrent
igure 4. Pre-intervention, post-intervention, and follow-up angiograms,
ollow-up angiograms correspond to the intravascular ultrasound examples a
s heterogeneous stent strut distribution. Note that the three struts marke
ith more neointimal hyperplasia. (From Takebayashi et al. [35].)esions had an MSA 4.0 mm2 versus 4 nonrecurrences (p  0.02); and a gap between Cypher stents was identified
n 3 recurrences versus 1 nonrecurrence (39). Recurrent IH
ften appeared echolucent, especially in patients with pre-
ious brachytherapy failures (40).
axus stent. In the TAXUS-V ISR, %IH volume mea-
ured 12.2 10.3% in 42 patients treated with Taxus stents.
G. W. Stone, unpublished data, 2006). However, predic-
ors of recurrence have not been reported.
LINICAL USES OF IVUS IN THE DES ERA
here are no studies specifically addressing the clinical
tility of IVUS in the DES era. In particular, there are no
andomized angiographic versus IVUS trials.
ssessment and treatment of intermediate stenoses. In
he BMS era, a minimal luminal CSA4.0 mm2 in a major
ctively, are shown at top; slices a b, and c in the post-intervention and
tom. In slice b, corresponding to the center of the in-stent restenosis, there
the asterisk are farther apart than the others and that this is associatedrespe
t bot
d with3 mm) epicardial vessel (excluding the left main coronary
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August 1, 2006:421–9 IVUS and DESrtery [LMCA]) correlated with ischemia, and a minimal
uminal CSA 4.0 mm2 was associated with a low rate of
vents with medical therapy (41,42). Moses et al. (43) reported
67 patients with intermediate lesions (angiographic diame-
er stenosis 50%) from the SIRIUS, TAXUS-IV, and
UTURE I/II (First Use to Underscore Restenosis Reduc-
ion With Everolimus) trials. At 1 year, patients treated
ith DES had similar rates of cardiac death or MI (3.4% vs.
.4% in BMS; p  0.49) and fewer target vessel revascu-
arizations (3.4% vs. 20.3%; p  0.0004), major adverse
ardiac events (5.6% vs. 25.4%; p  0.0003), and binary
ngiographic restenoses (1.8% vs. 34.0%; p  0.0001); no
atient in either group developed stent thrombosis. Stenting
f borderline lesions was safe, with a rate of events similar
o deferred intervention, questioning the need for IVUS
r physiologic assessment of intermediate non-LMCA
esions. Conversely, routine DES implantation was not
etter than judicious decision-making and was presumably
ore expensive. Intravascular ultrasound can also unmask
ccult stenoses that may warrant treating with a second or a
onger first DES (44).
cute DES expansion, stent apposition, and full lesion
overage. As noted in the preceding, the single number
hat best predicts an adequate IVUS minimum lumen CSA
t follow-up or freedom from angiographic restenosis is a
ypher MSA of 5.0 to 5.5 mm2. Is this always adequate?
irst, there are no similar data with Taxus stents. Second,
here is still a step-wise relationship between a larger MSA
nd a lower restenosis rate. Third, SIRIUS trial patients are
ow risk. Fourth, even this modest cut-off is often not
chieved. Interventionalists routinely rely on manufacturer-
upplied compliance charts to target final stent dimensions
ased on stent size and inflation pressure. However, a
ritical IVUS analysis shows that: 1) Cypher and Taxus
chieve only 75  10% of predicted minimal stent diameter
nd 66  17% of predicted MSA; and 2) approximately
5% of Cypher and Taxus implanted into 3.0-mm vessels
o not achieve an MSA of 5.0 mm2 (45). Thus,
anufacturer-supplied charts underestimate final stent size.
Full stent-vessel wall apposition appeared to be less
mportant than adequate stent expansion. In the study by
ong et al. (26), post-procedure (acute) incomplete stent
pposition was observed in 51 DES-treated lesions (7.2%).
here were no major adverse cardiac events (including
arget lesion revascularization), and maximum intra-stent
H CSA at follow-up measured 1.2  0.5 mm2, similar to
tents with complete apposition. In another IVUS study of
ncompletely apposed Cypher stents, IH at the site of
omplete malapposition resolution was many times greater
han at the site of persistent stent malapposition, and no
atient developed angiographic restenosis (46). In the
AXUS-II trial, 8 of 13 acute stent malappositions in the
low-release group resolved, all acute stent malappositions
n the moderate-release group resolved, and at 12 months
cute stent malappositon was not associated with an increase
n adverse clinical events (24). Thus, initial concerns that
D
ucute incomplete stent apposition would affect drug delivery
o the vessel wall and lead to DES failure appeared to be
nfounded, and aggressive adjunct inflations to eliminate
cute stent malapposition seemed unwarranted.
The restenosis penalty of longer DES is less than after
MS supporting “full DES lesion coverage” (47). Intravas-
ular ultrasound can be used to identify the proximal and
istal reference sites (cross-sections with the largest lumen
nd least plaque), to measure the distance between these two
ites using motorized transducer pullback, and to avoid
lacing the stent edge into a plaque, a predictor of edge
estenosis (18). Selecting the correct DES length the first
ime should be cost-effective compared with having to
mplant a second, overlapping stent, and it may be associ-
ted with fewer acute complications (48).
pecific patient and lesion subsets. Patients at higher risk
or Cypher stent thrombosis (49) or restenosis (38) have
een described. Whenever these risk factors are present or
hen consequences of failure would be significant (i.e.,
nprotected LMCA lesions) (Table 1), stent dimensions
hould be optimized for vessel size rather than settling for
n MSA of 5.0 to 5.5 mm2. For example, in one published
tudy of 102 patients with LMCA disease treated with
ypher stents where IVUS guidance was used in 86%, MSA
easured 9.6  2.6 mm2, and 1-year target lesion revascu-
arization was necessary in only 2 patients (50). Similarly, in
8 patients with ostial left anterior descending (LAD)
tenoses treated with Cypher stents, the MSA measured
.4  1.4 mm2, distal LMCA involvement (angiographic
iameter stenosis 30% and IVUS plaque burden 40%)
as covered with longer stents, only 5.1% developed angio-
raphic restenosis, and none required target lesion revascu-
arization (51). (Conversely, an MSA of 5.0 mm2 may not
e achievable in small vessels, because it corresponds to a 0%
esidual stenosis in a 2.5-mm vessel and a negative residual
tenosis in a 2.5-mm vessel; but it still can be vessel size
ptimized, and stent expansion [MSA/reference lumen
rea] in smaller vessels may be the best predictor of an
dequate lumen at follow-up [52].)
A recent analysis of LAD/diagonal bifurcation lesions
reated with the crush technique found the MSA at the side
able 1. Indications for IVUS Imaging During DES
mplantation
igh-risk patient subsets
1) Renal failure (45)
2) Limitations to dual antiplatelet therapy use (45)
3) Diabetes mellitus (34,45)
4) Poor left ventricular function (45)
igh-risk lesion subsets
1) Left main disease
2) Bifurcations (34,45)
3) Ostial lesions (34)
4) Small vessels (34)
5) Long lesions (34)
6) Treatment of ISR (34)ES  drug-eluting stent; ISR  in-stent restenosis; IVUS  intravascular
ltrasound.
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IVUS and DES August 1, 2006:421–9ranch ostium in 68%, where it measured 4 mm2 in 44%
nd5 mm2 in 82% (53). When treating bifurcation lesions
ith DES, it may be necessary to pay more attention to the
ide branch ostium, the most common restenosis location,
han was done in the BMS era. Pre-intervention IVUS can
etermine whether the side branch is involved, whether it is
iseased but not stenotic, or whether it is stenotic. Post-
ntervention imaging can determine whether the side
ranch has been compromised (after provisional stenting) or
hether there is adequate stent expansion (after stenting
oth branches). However, IVUS can not adequately assess
he side branch from the main vessel; it is necessary to image
he side branch directly.
ES failure. Currently, IVUS is the best way to identify
nd exclude causes of DES failure. All DES failures warrant
VUS study.
The optimal treatment for DES failure is not clear. At
he least, underexpanded stents (the most common mech-
nism) should be properly expanded before placing another
ES to avoid perpetuating the problem. (It is unclear
hether merely expanding an underexpanded DES will be
ffective, because the drug has already been eluted and
dditional expansion may cause vessel trauma.)
Concerns regarding LSM have been minimized. Late
tent malapposition appears to be stable or regress and does
ot appear to warrant catheter-based treatment.
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